Navigating systemic therapy for metastatic castration-naïve prostate cancer

被引：0
|
作者：
E. M. Kwan
I. A. Thangasamy
J. Teh
O. Alghazo
N. J. Sathianathen
N. Lawrentschuk
A. A. Azad
机构：
[1] Monash University,Department of Medicine, School of Clinical Sciences
[2] Monash Health,Department of Medical Oncology
[3] University of Melbourne,Division of Cancer Surgery, Peter MacCallum Cancer Centre
[4] University of Queensland,Faculty of Medicine
[5] University of Melbourne,Department of Surgery
[6] Austin Hospital,Department of Medical Oncology
[7] Peter MacCallum Cancer Centre,Sir Peter MacCallum Department of Oncology
[8] University of Melbourne,undefined
来源：
World Journal of Urology | 2021年 / 39卷
关键词：
Metastatic prostate cancer; Castration-naïve; Hormone-sensitive; Androgen receptor pathway inhibitors; Docetaxel; Abiraterone; Enzalutamide; Apalutamide;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：339 / 348
页数：9
相关论文
共 50 条
  • [41] Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology
    Nuhn, Philipp
    De Bono, Johann S.
    Fizazi, Karim
    Freedland, Stephen J.
    Grilli, Maurizio
    Kantoff, Philip W.
    Sonpavde, Guru
    Sternberg, Cora N.
    Yegnasubramanian, Srinivasan
    Antonarakis, Emmanuel S.
    EUROPEAN UROLOGY, 2019, 75 (01) : 88 - 99
  • [42] Cardiovascular Risks and Survival with Abiraterone vs Enzalutamide in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer in Germany: AVENGER Study
    Axel S. Merseburger
    Eugen Dornstauder
    Carsten-Henning Ohlmann
    Armen Aprikian
    Sophia Junker
    Philipp Hahn
    Andrew Chilelli
    Matthias Stoelzel
    Alexis Serikoff
    Stefan G. Spitzer
    Advances in Therapy, 2025, 42 (4) : 1919 - 1934
  • [43] Factors influencing survival in metastatic castration-resistant prostate cancer therapy
    Marchioni, Michele
    Marandino, Laura
    Amparore, Daniele
    Berardinelli, Francesco
    Mascitti, Marco
    Ferro, Matteo
    Campi, Riccardo
    Schips, Luigi
    EXPERT REVIEW OF ANTICANCER THERAPY, 2022, 22 (10) : 1061 - 1079
  • [44] Therapy decisions for the symptomatic patient with metastatic castration-resistant prostate cancer
    Markowski, Mark C.
    Pienta, Kenneth J.
    ASIAN JOURNAL OF ANDROLOGY, 2015, 17 (06) : 936 - 938
  • [45] Current therapy and drug resistance in metastatic castration-resistant prostate cancer
    Cai, Maoping
    Song, Xian-Lu
    Li, Xin-An
    Chen, Mingkun
    Guo, Jiading
    Yang, Dong Hua
    Chen, Zhanghui
    Zhao, Shan-Chao
    DRUG RESISTANCE UPDATES, 2023, 68
  • [46] Second-Line Therapy in metastatic castration refractory Prostate Cancer (mCRPC)
    Rexer, H.
    Graefen, M.
    Merseburger, A.
    UROLOGE, 2019, 58 (03): : 359 - 360
  • [47] Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches
    Zool Hilmi Awang
    Markus Essler
    Hojjat Ahmadzadehfar
    Radiation Oncology, 13
  • [48] Abiraterone and enzalutamide in the first line therapy of metastatic castration resistant prostate cancer
    Al-Samsam, Sofya
    Bartos, Jiri
    Samal, Vladimir
    Dvorak, Josef
    Kolarova, Hana
    Richter, Igor
    REPORTS OF PRACTICAL ONCOLOGY AND RADIOTHERAPY, 2024, 29 (01) : 1 - 9
  • [49] Metastatic castration-resistant prostate cancer-emerging trends in therapy
    von Amsberg, Gunhild
    Todenhoefer, Tilman
    UROLOGIE, 2023, : 1289 - 1294
  • [50] Metastatic castration-resistant prostate cancer therapy: the quest for the perfect molecule
    Bianco, Davide
    Nappi, Carmela
    Klain, Michele
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 (03) : 883 - 884
12345